Jushi Holdings Valuation
Is JUSH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of JUSH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate JUSH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate JUSH's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JUSH?
Key metric: As JUSH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is JUSH's PS Ratio? | |
|---|---|
| PS Ratio | 0.3x |
| Sales | US$259.44m |
| Market Cap | US$68.30m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | 6.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does JUSH's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.6x | ||
AYR.A Ayr Wellness | 0.2x | 2.5% | CA$111.7m |
HLS HLS Therapeutics | 1.4x | 8.6% | CA$112.9m |
RX BioSyent | 3.8x | 12.9% | CA$131.9m |
VREO Vireo Growth | 0.8x | 3.4% | CA$109.4m |
JUSH Jushi Holdings | 0.3x | 8.7% | CA$68.3m |
Price-To-Sales vs Peers: JUSH is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1.6x).
Price to Sales Ratio vs Industry
How does JUSH's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?
| 29 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 0.9x | 10.7% | |
JUSH Jushi Holdings | 0.3x | 8.7% | US$68.30m |
AYR.A Ayr Wellness | 0.2x | 2.5% | US$79.76m |
IAN iAnthus Capital Holdings | 0.3x | n/a | US$47.66m |
| 29 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 0.9x | 53.8% | |
JUSH Jushi Holdings | 0.3x | 25.4% | US$68.30m |
Price-To-Sales vs Industry: JUSH is good value based on its Price-To-Sales Ratio (0.3x) compared to the Canadian Pharmaceuticals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is JUSH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.3x |
| Fair PS Ratio | 0.8x |
Price-To-Sales vs Fair Ratio: JUSH is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Cresco Labs
CA$727.2m
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.
CL
CA$1.65
7D
9.3%
1Y
-31.3%
Decibel Cannabis
CA$30.0m
An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.
DB
CA$0.065
7D
0%
1Y
-53.6%
Bausch Health Companies
US$3.1b
Operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
BHC
US$11.95
7D
7.0%
1Y
20.3%